MIST Milestone Pharmaceuticals
- 1.740
- -0.010-0.57%
- 1.720
- -0.020-1.13%
Milestone Pharmaceuticals News
Milestone Pharmaceuticals Analyst Ratings
Milestone Pharmaceuticals' Strong Buy Rating: CARDAMYST's FDA Resubmission and Bright Revenue Prospects
Milestone Pharmaceuticals Analyst Ratings
Analysts' Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Milestone Pharmaceuticals Analyst Ratings
Milestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial Outlook
Bullish Outlook on Milestone Pharmaceuticals Amid Regulatory Hurdles: A Buy Rating With a $25 Price Target
Analysts Conflicted on These Healthcare Names: Oramed Pharm (ORMP), Accolade (ACCD) and Milestone Pharmaceuticals (MIST)
TD Cowen Maintains Outperform on Milestone Pharmaceuticals, Lowers Price Target to $9
Milestone Pharmaceuticals Analyst Ratings
Milestone Pharmaceuticals Earns Buy Rating Amid Promising Clinical Trials and Market Potential
Promising Future for Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Encouraging Etripamil Trial Outcomes and Projected Revenue Growth
Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Milestone Pharmaceuticals (MIST)
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals Analyst Ratings
Milestone Pharmaceuticals (MIST) Gets a Buy From H.C. Wainwright
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating
Piper Sandler Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)
Analysis
Price Target
No Data
